Insider Transactions in Q2 2024 at Edgewise Therapeutics, Inc. (EWTX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2024
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,157
-5.77%
|
$38,826
$18.91 P/Share
|
|
May 02
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
1,956
-37.56%
|
$35,208
$18.91 P/Share
|
|
May 02
2024
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
3,152
-17.88%
|
$56,736
$18.91 P/Share
|
|
May 02
2024
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
3,682
-15.62%
|
$66,276
$18.91 P/Share
|
|
May 02
2024
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,576
-17.88%
|
$28,368
$18.91 P/Share
|
|
May 02
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,718
-11.35%
|
$30,924
$18.91 P/Share
|
|
May 01
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+12.23%
|
-
|
|
May 01
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+50.0%
|
-
|
|
May 01
2024
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+37.14%
|
-
|
|
May 01
2024
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+30.64%
|
-
|
|
May 01
2024
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+37.14%
|
-
|
|
May 01
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+25.59%
|
-
|